ClinicalTrials.gg
Enrolling by invitationNCT07948993Updated Nov 19, 2026

VOSE vs. MOSE in EUS-FNB for Pancreatic Masses

An interventional study of VOSE Group (Visual On-Site Evaluation and MOSE(Macroscopic On-Site Evaluation) in Pancreatic Neoplasms, sponsored by Ruijin Hospital. Enrolling by invitation at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Ruijin Hospital · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled May 2026, registered Nov 2026).
Updated Nov 19, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
472
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 29 studies in Pancreatic Neoplasms by Ruijin Hospital — 20 open to participants now, 20 under way, none of them phase 3. Pancreatic Neoplasms · Ruijin Hospital.

Planned enrollment
Largest of 19
472 · median 54
Started
2026
with 6 others
No phase
6 of 29
3 open now
Primary completion
2027-05
later than 11 of 19 live
Registered
29th of 29
by date

Among the 29 studies in Pancreatic Neoplasms by Ruijin Hospital, this one has the largest planned enrollment of the 19 interventional ones that give a count, is one of 7 that started in 2026, is one of 6 with no phase, reaches primary completion later than 11 of the 19 other live ones, and was the 29th registered.

Pancreatic Neoplasms

3,902 studies on the registry are indexed under Pancreatic Neoplasms; 1,004 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

20 of the 29 studies in Pancreatic Neoplasms by Ruijin Hospital are open now, in 1 country. Recruiting first, the newest first:

14 more — sign in →

By country, each count listing its studies:

All 20 open studies →

Where they have run

Who these studies take

Of the 741 Pancreatic Neoplasms studies recruiting now, 475 (64%) set no upper age limit and 152 (21%) stop at 75 or younger; 40 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Pancreatic Neoplasms by Ruijin Hospital, or all of them as a file.
02

Study summary

The primary endpoint of this study was to evaluate whether the histopathological diagnostic accuracy of VOSE EUS-FNB using 22-gauge (22G) Franseen or 22G Trident (Trident™) needles is non-inferior to that of MOSE EUS-FNB in pancreatic solid masses. The secondary endpoints included diagnostic sensitivity, diagnostic specificity, median number of needle passes, puncture time, and cytological diagnostic accuracy.

03

Conditions studied

  • Pancreatic Neoplasms
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age above 18 years, male or female.
  • Presence of a solid pancreatic mass detected by CT, MRI, PET-CT, or EUS, and scheduled for EUS-FNB for diagnostic purposes.
  • Provision of signed written .

Exclusion criteria

Exclusion Criteria:

  • to endoscopy, such as severe cardiovascular or cerebrovascular diseases.
  • Coagulation disorders ( [INR] ≥ 1.5, count ≤ 50 × 10\^9/L) or current use of anticoagulant or antiplatelet medications.
  • Confirmed or suspected pregnancy.
  • Pathological diagnosis has already been established by other methods.
  • Refusal to participate in the study, current participation in another clinical trial, or participation in another clinical trial within 60 days prior to enrollment.
  • Any other conditions that preclude the performance of EUS-FNB.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
472 participants (estimated)

Study arms

  • Experimental
    VOSE Group (Visual On-Site Evaluation)

    Patients undergo EUS-FNB using 22G Franseen or 22G Trident needles. The first pass specimen is pushed onto a slide, and visible tissue cores are placed into formalin for visual grading. If no "red mixed specimen" is observed, additional passes are performed up to 3 passes. The number of passes and puncture time are recorded.

    Diagnostic Test: VOSE Group (Visual On-Site Evaluation

  • Active comparator
    MOSE Group (Macroscopic On-Site Evaluation)

    Patients undergo EUS-FNB using 22G Franseen or 22G Trident needles. The first pass specimen is pushed onto a slide, and the macroscopic visible core (MVC) length is measured. If the MVC is \< 10mm, additional passes are performed until the total MVC is ≥ 10mm or up to 3 passes. The number of passes and puncture time are recorded.

    Diagnostic Test: MOSE(Macroscopic On-Site Evaluation)

Interventions

  • Diagnostic testVOSE Group (Visual On-Site Evaluation

    VOSE group:During the EUS-FNB procedure, the first-pass specimen is pushed onto a slide. Visible tissue cores are placed into a formalin vial, gently shaken to dissolve blood, and visually graded with photographic recording. If the first-pass specimen is not a "red mixed specimen," additional passes are performed until a "red mixed specimen" appears or a maximum of 3 passes is reached.

  • Diagnostic testMOSE(Macroscopic On-Site Evaluation)

    MOSE group:During the EUS-FNB procedure, the first-pass specimen is pushed onto a slide, and the length of the macroscopic visible core (MVC) is measured. If the total MVC length is less than 10 mm, additional passes are performed until the total MVC is ≥ 10 mm or a maximum of 3 passes is reached.

06

What researchers measure

Primary outcomes

  1. Histopathological diagnostic accuracy

    The diagnostic accuracy of histopathological tissue obtained by EUS-FNB in the VOSE group compared to the MOSE group, using the final surgical pathology or clinical/radiological follow-up as the gold standard.

    Time frame: Within 30 days after the EUS-FNB procedure

Secondary outcomes

  1. Diagnostic sensitivity

    The diagnostic sensitivity of VOSE and MOSE groups compared to the final gold standard diagnosis.

    Time frame: Within 30 days after the EUS-FNB procedure

  2. Diagnostic specificity

    The diagnostic specificity of VOSE and MOSE groups compared to the final gold standard diagnosis.

    Time frame: Within 30 days after the EUS-FNB procedure

  3. Median number of needle passes

    The number of needle passes required to obtain adequate tissue samples (until a "red mixed specimen" or MVC ≥ 10mm is observed, up to 3 passes).

    Time frame: During the EUS-FNB procedure

  4. Puncture time

    The duration of the puncture procedure (from the start of the first needle pass to the end of sampling).

    Time frame: During the EUS-FNB procedure

  5. Cytological diagnostic accuracy

    The diagnostic accuracy of liquid-based cytology obtained from residual specimens in VOSE and MOSE groups, compared to the final gold standard diagnosis.

    Time frame: Within 30 days after the EUS-FNB procedure

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for May 2027, 12 months after the start.

Of 404 non-industry interventional studies with no phase under Pancreatic Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 75. This study's planned 12 months is below that.

Counting every sponsor, half of 431 studies reached it within 44 months; a quarter within 26 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2026
First posted
Nov 19, 2026
StartActual
May 1, 2026
Primary completionEst.
May 1, 2027
CompletionEst.
Dec 1, 2027
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07948993
Lead sponsor
Ruijin Hospital
Collaborators
First Affiliated Hospital of Naval Medical University, The Affiliated Hospital Of Southwest Medical University, Chengdu Third People's Hospital, The Affiliated Hospital of Qingdao University, Shenzhen People's Hospital, First Affiliated Hospital Xi'an Jiaotong University, The First Affiliated Hospital of Nanchang University
Responsible party
Sponsor
First posted
Nov 19, 2026
Start date
May 1, 2026
Primary completion
May 1, 2027 (estimated)
Completion
Dec 1, 2027 (estimated)
Last update
Nov 19, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion